SGLT2 Inhibitors and Diabetic Kidney Disease
This special episode is made possible by an unrestricted educational grant from AstraZeneca.
In this special episode of Diabetes Core Update, Drs. Neil Skolnik and John Russell of Abington Memorial Hospital and the Temple University School of Medicine will present and discuss the beneficial effects of SGLT2 inhibitors on kidney function. SGLT2 inhibitors are a class of medication used to help lower blood glucose levels in people with type 2 diabetes, but recent trials have shown that SGLT2 inhibitors can also help slow the progression of diabetic kidney disease and chronic kidney disease. Drs. Skolnik and Russell will discuss these trials; the exciting data showing the beneficial effects of SGLT2 inhibitors on diabetic kidney disease; recommendations for screening for and diagnosing kidney disease in people with diabetes; and strategies for educating patients about renal disease.Users can listen to each episode by clicking on the podcast players below or subscribe on Apple Podcasts or Google Play.
SGLT2 INHIBITORS AND DIABETIC KIDNEY DISEASE
Post Date: September 27, 2021
American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167. doi: 10.2337/dc21-S011. Erratum in: Diabetes Care. 2021 Sep;44(9):2186-2187. PMID: 33298422.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511. PMID:33031522; PMCID: PMC7542529.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.
Stempniewicz N, Vassalotti JA, Cuddeback JK, Ciemins E, Storfer-Isser A, Sang Y, Matsushita K, Ballew SH, Chang AR, Levey AS, Bailey RA, Fishman J, Coresh J. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care. 2021 Sep;44(9):2000-2009. doi: 10.2337/dc20-2715. Epub 2021 Jul 7. PMID: 34233925.
Alfego D, Ennis J, Gillespie B, Lewis MJ, Montgomery E, Ferrè S, Vassalotti JA, Letovsky S. Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Diabetes Care. 2021 Sep;44(9):2025-2032. doi: 10.2337/dc21-0723. Epub 2021 Aug 5. PMID: 34353883.
Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, and Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 Mar;99(3):750-762. doi: 10.1016/j.kint.2020.10.031. Epub 2020 Nov 10. PMID: 33181154.
Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 Apr;99(4):999-1009. doi: 10.1016/j.kint.2020.10.042. Epub 2020 Dec 11. PMID: 33316282.
Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018 Nov 1;33(11):2005-2011.PMID: 29370424; PMCID: PMC6212718.
Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals: Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Users can freely access previous episodes of Diabetes Core Update here.